Genor Biopharma Holdings Limited (6998.HK)
6998.HK Stock Price Chart
Explore Genor Biopharma Holdings Limited interactive price chart. Choose custom timeframes to analyze 6998.HK price movements and trends.
6998.HK Company Profile
Discover essential business fundamentals and corporate details for Genor Biopharma Holdings Limited (6998.HK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
7 Oct 2020
Employees
24.00
Website
https://www.genorbio.comCEO
Feng Guo
Description
Genor Biopharma Holdings Limited, a biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally. The company's principal drug candidates include GB242, an infliximab (Remicade) biosimilar for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, adult and pediatric crohn's disease, and fistulising crohn's disease; GB491 (lerociclib), an oral CDK4/6 inhibitor for treating hormone receptor-positive (HR+)/HER2- breast cancer and is under Phase III clinical trials; and GB492, a stimulator of interferon genes (STING) agonist expected to exert synergistic effects in combination with GB226 for solid tumors and is under Phase 1/2 clinical trial. Further, it develops GB221, a herceptin (trastuzumab)-mimic HER2 monoclonal antibody (mAb) drug candidate; geptanolimab (GB226), a novel PD-1 mAb drug candidate; GB223, a receptor activator of nuclear factor-B Ligand (RANKL) mAb drug candidate, which is under Phase I clinical trial; and GB261 to treat B-cell non-Hodgkin Lymphoma and is under Phase I Clinical trials. In addition, the company's product candidates under clinical trials include GB262, GB264, GB265, and GB 266 for the treatment of cancer. Genor Biopharma Holdings Limited was formerly known as JHBP (CY) Holdings Limited and changed its name to Genor Biopharma Holdings Limited in June 2021. The company was founded in 2007 and is headquartered in Shanghai, China.
6998.HK Financial Timeline
Browse a chronological timeline of Genor Biopharma Holdings Limited corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 26 Mar 2026
Upcoming earnings on 26 Mar 2026
Earnings released on 26 Aug 2025
Earnings released on 26 Aug 2025
Earnings released on 28 Mar 2025
EPS came in at $0.08 , while revenue for the quarter reached $102.00M .
Earnings released on 25 Mar 2025
EPS came in at $0.08 , while revenue for the quarter reached $106.10M .
Earnings released on 28 Aug 2024
EPS came in at -$0.13 , while revenue for the quarter reached $7.77M .
Earnings released on 28 Jun 2024
EPS came in at -$0.13 , while revenue for the quarter reached $7.83M .
Earnings released on 29 Mar 2024
EPS came in at -$0.44 .
Earnings released on 27 Mar 2024
EPS came in at -$0.42 surpassing the estimated -$0.54 by +21.51%.
Earnings released on 31 Aug 2023
EPS came in at -$0.29 surpassing the estimated -$0.62 by +52.35%.
Earnings released on 31 Mar 2023
EPS came in at -$0.36 surpassing the estimated -$0.55 by +34.58%, while revenue for the quarter reached $7.39M , missing expectations by -91.63%.
Earnings released on 31 Mar 2023
EPS came in at -$0.31 .
Earnings released on 30 Sept 2022
EPS came in at -$0.35 , while revenue for the quarter reached $7.13M .
Earnings released on 31 Aug 2022
EPS came in at -$0.48 surpassing the estimated -$1.25 by +62.05%, while revenue for the quarter reached $1.73M , missing expectations by -97.40%.
Earnings released on 31 Mar 2022
EPS came in at -$0.50 , while revenue for the quarter reached $1.82M .
Earnings released on 31 Mar 2022
EPS came in at -$0.57 .
Earnings released on 30 Sept 2021
EPS came in at -$0.56 surpassing the estimated -$2.07 by +72.94%.
Earnings released on 27 Aug 2021
EPS came in at -$0.48 surpassing the estimated -$1.50 by +67.85%.
Earnings released on 30 Jun 2021
EPS came in at -$0.49 .
Earnings released on 23 Mar 2021
EPS came in at -$5.62 , while revenue for the quarter reached $3.75M .
Earnings released on 31 Dec 2020
EPS came in at -$5.85 , while revenue for the quarter reached $3.90M .
Earnings released on 23 Sept 2020
EPS came in at -$0.32 .
6998.HK Stock Performance
Access detailed 6998.HK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.